Skip to content

US · IMDX · MEDICAL - DIAGNOSTICS & RESEARCH

Insight Molecular Diagnostics Inc. (IMDX) intrinsic value and stock valuation

$1.97as of 2026-11-21 · Mkt cap 155.96M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Insight Molecular Diagnostics Inc. DCF and intrinsic value

InvestorsCraft values IMDX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IMDX’s statements →

Insight Molecular Diagnostics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Nashville, TN 37217 imdxinc.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$4.05M+27.1% 5y CAGRd
20132025
Net income
-$-50.22M
20132025
Free cash flow
-$-25.37M
20132025
Total equity
-$-31.46M
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$4.05M$1.88M$1.5M$960K$2.2M
Operating income-$-30.58M-$-61.04M-$-25.14M-$-18M-$-53.73M
Net income-$-50.22M-$-60.66M-$-27.78M-$-72.9M-$-64.1M
EPSd-$-1.65M-$-4.64M-$-3.63M-$-13.16M-$-14.4M
Operating cash flow-$-22.18M-$-20.71M-$-23.32M-$-45.57M-$-35.94M
Capital expenditure-$-3.19M-$-520K-$-280K-$-4.34M-$-2.25M
Free cash flow-$-25.37M-$-21.23M-$-23.61M-$-49.91M-$-38.19M
Total assets$25.8M$35.1M$74.9M$100.1M$159.6M
Total debt$3.5M$3.66M$2.87M$3.54M$5.68M
Net debt-$-8.09M-$-4.97M-$-6.56M-$-16.45M-$-27.27M
Total equity-$-31.46M-$-12.27M$20.5M$39.6M$65.2M
Cash and short-term investments$11.6M$8.64M$9.43M$20.4M$33.9M
Income statement
20252024202320222021
Revenue$4.05M$1.88M$1.5M$960K$2.2M
Cost of revenue$3.87M$1.14M$1.09M$980K$780K
Gross profit$190K$740K$410K-$-20K$1.42M
Research and development expenses$15.9M$9.84M$9.29M$7.3M$5.04M
Selling, general and administrative expenses$17M$13.8M$13.3M$21.5M$20.4M
Other expenses-$-2.11M$38.2M$2.97M-$-10.86M$29.7M
Operating expenses$30.8M$61.8M$25.6M$18M$55.2M
Cost and expenses$34.6M$62.9M$26.6M$19M$55.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$110K$80K$50K$80K$210K
Depreciation and amortization$2.2M$1.56M$1.68M$5.22M$4.21M
Ebitda-$-47.92M-$-59.02M-$-23.12M-$-13.31M-$-48.46M
Operating income-$-30.58M-$-61.04M-$-25.14M-$-18M-$-53.73M
Total other income/expenses, net-$-19.64M$380K$280K-$-610K$850K
Income before tax-$-50.22M-$-60.66M-$-24.86M-$-18.61M-$-52.87M
Income tax expense$0.00$0.00$0.00$0.00-$-9.26M
Net income-$-50.22M-$-60.66M-$-27.78M-$-72.9M-$-64.1M
Weighted average shares outstanding$30.5M$13.1M$7.65M$5.54M$4.45M
Weighted average diluted shares outstanding$30.5M$13.1M$7.65M$5.54M$4.45M
Balance sheet
20252024202320222021
Cash and short-term investments$11.6M$8.64M$9.43M$20.4M$33.9M
Net receivables$1.13M$1.61M$480K$2.01M$1.44M
Inventory$450K$410K$0.00$0.00$300K
Total current assets$15.3M$11.8M$10.7M$25.5M$39.1M
Property, plant and equipment, net$2.81M$2.76M$5.44M$10.9M$8.37M
Goodwill and intangible assets$0.00$14.6M$56.6M$61.6M$80.4M
Long-term investments$610K$1.7M$0.00$0.00$0.00
Total non-current assets$10.5M$23.3M$64.2M$74.6M$120.4M
Total assets$25.8M$35.1M$74.9M$100.1M$159.6M
Accounts payable$2.54M$2.28M$950K$1.25M$1.81M
Short-term debt$1.81M$1.29M$670K$810K$2.13M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$12.1M$7.28M$7.19M$12.1M$14.1M
Long-term debt$1.69M$2.37M$2.2M$2.73M$3.54M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$45.2M$40.1M$47.2M$48.4M$80.2M
Capital lease obligations$3.5M$3.66M$2.87M$3.54M$4.36M
Total liabilities$57.2M$47.4M$54.4M$60.5M$94.4M
Common stock$369.2M$338.2M$310.3M$294.9M$253M
Retained earnings-$-400.76M-$-350.54M-$-289.88M-$-260.68M-$-187.77M
Accumulated other comprehensive income (loss)$90K$20K$50K$40K$40K
Total equity-$-31.46M-$-12.27M$20.5M$39.6M$65.2M
Total investments$610K$1.7M$0.00$430K$900K
Total debt$3.5M$3.66M$2.87M$3.54M$5.68M
Net debt-$-8.09M-$-4.97M-$-6.56M-$-16.45M-$-27.27M
Cash flow statement
20252024202320222021
Net income-$-50.22M-$-60.66M-$-27.78M-$-72.9M-$-64.1M
Depreciation and amortization$2.2M$1.56M$1.68M$5.22M$4.21M
Stock-based compensation$2.22M$1.91M$6.57M$10M$6.84M
Change in working capital$2.73M-$-1.32M-$-3.97M-$-1.94M$150K
Accounts receivable$480K-$-1.13M$110K-$-570K-$-1.23M
Inventory-$-40K-$-410K$0.00$0.00$0.00
Accounts payable$2.65M$970K-$-4.76M$300K-$-1.35M
Net cash provided by operating activities-$-22.18M-$-20.71M-$-23.32M-$-45.57M-$-35.94M
Investments in property, plant and equipment-$-3.19M-$-520K-$-280K-$-4.34M-$-2.25M
Acquisitions, net$0.00$0.00$0.00$0.00-$-11.71M
Net cash used for investing activities-$-3.19M-$-510K-$-930K-$-4.34M-$-13.96M
Common stock issued$28.7M$27.8M$13.9M$32.8M$78M
Common stock repurchased$0.00$0.00$0.00$0.00-$-240K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$28.1M$20.4M$12.2M$35.8M$78.4M
Net change in cash$3.68M-$-800K-$-12.07M-$-14.1M$28.5M
Cash at end of period$12.3M$10.3M$11.1M$23.2M$37.3M
Operating cash flow-$-22.18M-$-20.71M-$-23.32M-$-45.57M-$-35.94M
Capital expenditure-$-3.19M-$-520K-$-280K-$-4.34M-$-2.25M
Free cash flow-$-25.37M-$-21.23M-$-23.61M-$-49.91M-$-38.19M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Insight Molecular Diagnostics Inc.

        OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

        CEO
        Joshua Riggs
        Employees
        58
        Beta
        1.76

        Explore

        Frequently asked questions

        What is the intrinsic value of Insight Molecular Diagnostics Inc. (IMDX)?

        Insight Molecular Diagnostics Inc. (IMDX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IMDX undervalued?

        IMDX trades at a price of $1.97 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.